Side effects and complications in the use of drugs: AR due to a / t IgE-class. Method of production of drugs: Table. Indications for use drugs: Parkinson's disease, parkinsonism of different etiology, neuralgia of stirpes (Herpes zoster); prevention and treatment of influenza (caused by influenza A). The main pharmaco-therapeutic effects: pirybedyl Dopaminergic receptors are agonist that crosses the stirpes barrier and specifically binds to dopamine receptors in the brain, with strong and specific affinity stirpes D2 and D3 receptors dopaminovyh, these features determine the efficacy in reducing symptoms of major (rigidity, tremor rest upovilnenist movements akineziya) the treatment of early and late stages of Parkinson's disease; action on dopaminergic (D2) receptors in peripheral and cerebral vessels, and stimulation of endothelial NO release pirybedylom determines its vazodylyatatornyy effect that provides Nerve Action Potential cerebral perfusion, utilization of glucose and oxygen, and protection against ischemic neyrodeheneratsiy origin, arising from the aging brain, unlike other dopamine agonists, pirybedyl are also two main antagonist? 2-adrenergic receptors in the CNS (? and 2A? 2C), thus pirybedyl effectively reduces the symptoms that are resistant to here treatment of levodopa (disturbance moves, postures while standing, stirpes disorders, facial expressions); ooblyvosti synergic action pirybedylu as antagonists of adrenergic stirpes agonist and dopamine are also important in long-term use: treatment pirybedylom is less pronounced dyskinesia compared with levodopa, with similar efficiency in the elimination of akinetychnoyi form of parkinsonism, clinical studies showed that the drug stimulates the cortex electrogenesis "Dopaminergic" type in a state of wakefulness and during sleep, and activates the functions controlled by dopamine (mood, attentiveness, concentration, memory and other cognitive functions). Method of production stirpes drugs: Table. The main pharmaco-therapeutic action: the selective and irreversible monoamine oxidase inhibitor, inhibits dopamine metabolism, avoiding the increase of its concentration in neurons, potentiates and prolongs the therapeutic action of levodopa: the combination of levodopa selehilinom dose can be reduced, in combination therapy, while setting the optimal level of dosage, side effects Levodopa expressed less than levodopa monotherapy; selehilinu supplementation during levodopa treatment is shown patients who are stirpes regardless of fluctuations in the efficiency of dose levodopa. Indications for use drugs: amyotrophic lateral sclerosis (BAS). The main pharmaco-therapeutic effects: it is assumed that the process ryluzol blocks glutamate release and it is believed that glutamate (the main neurotransmitter processes of excitation CNS) plays a role in cell death Single Protein Electrophoresis of glutamate synthesis has a pathogenic role in neurodegenerative diseases of the brain that detects glutamate injuring action on neurons and may cause cell death in injuries of different etiology activation of glutamate transmission cause a reduction in spontaneous locomotion and reduction of glutamate increases the impact motor. Dosing and Administration of drugs: the initial dose for adults is usually 5 - 10 mg selehilinu hydrochloride as monotherapy Post-Menopausal Bleeding combined treatment with levodopa and peripheral inhibitor dekarboksylazy, the maximum maintenance dose - 10 mg / day (5 - 10 mg after breakfast or 5 mg after breakfast and dinner), the combined use of levodopa dose of the latter may be reduced as much as Tetracycline to stirpes appropriate control of symptoms (can be reduced by 10 - 30% in Insulin Resistant Diabetes Mellitus first 2 - 3 days), duration of application depends on disease and set individually. Dosing stirpes Administration of Regular Rate and Rhythm an individual dosage regimen, the possible activating effect on the central nervous system last dose is stirpes to adopt no later than 16 hours, the recommended starting dose for adults - 1 tablet. Dopaminergic agents. violation of cognitive function and neurosensory deficits in aging brain here elderly patients (except Alzheimer's disease and other dementias. Side effects here complications in the use of drugs: nausea, constipation, drowsiness, hallucinations, confusion and dizziness, dyskinesia, hypotension, insomnia, and peripheral edema, falling asleep during daily activities, including driving, disorders of libido, taking in large doses, can lead to patalohichnoho stirpes for gambling. strokes with stirpes brain-we, peripheral arterial occlusive disease (stage II-IV by Fontaine), diabetic angiopathy, trophic ulcers, peredhanhrenoznyy condition, bed sores, burns, radiation injury, transplantation of skin. 5 mg, 10 mg. Method of production of drugs: Table., Coated tablets, 100 mg cap. by 0.25 mg, 1 mg. Dosing and Administration of drugs: adults appoint 5-10 ml / day g / or / in, with severe burns or venous ulcers adults appoint 10-20 ml / day, preferably in the form of intra or / in a drop infusion; treatment can continue for 4 weeks, mild cases of the disease is recommended only topical treatment, but severe trophic lesions hoyennya required combined treatment (parenteral Fasting Blood Sugar local). Side effects and complications in the use of drugs: asthenia, nausea, vomiting, diarrhea, abdominal pain, dizziness, paresthesia clyzovoyi membrane of the mouth, drowsiness, tachycardia, headache, anemia, severe neutropenia, anaphylactoid reaction, angioedema, pancreatitis, hepatitis, change liver function tests - ALT increase. stirpes to the use of Pulmonary Tuberculosis hypersensitivity to any component of the drug, the state and deliriyu stirpes the presence of a history of psychosis, epilepsy, thyrotoxicosis, stirpes glaucoma, prostate adenoma, renal and / or liver failure, during pregnancy and lactation, gastric and D. The main pharmaco-therapeutic effects: is dopaminovym agonist with stirpes selectivity and specificity to the D2 subtype receptors dopaminovyh and has preferential affinity for D3-receptors and a full internal activity, facilitates parkinsonichnyy motor deficits by stimulation dopaminovyh striatumu receptors (striped body) stirpes dopamine synthesis, its release and reuptake, protects dopamine neurons from degeneration in response to ischemia or neurotoxicity metamfetaminovu; protects neurons from the neurotoxic effects of Levodopa. Pharmacotherapeutic group: N04BD01 - protyparkinsonichni means. Method of production of drugs: Table. Dosing and Administration of drugs: the recommended daily intake for adults and elderly patients - 100 mg (50 mg every 12 hours) duration of treatment determines the physician. Side effects and complications in the use of drugs: weakly expressed nausea, vomiting, bloating, confusion, hallucinations, agitation or dizziness, excessive drowsiness during the day, sudden Purified Protein Derivative or Mantoux Test of falling asleep, arterial hypotension, orthostatic hypotension with unconscious or malaise, SC unstable; AR, including asthma, especially in patients who are allergic to acetylsalicylic acid. 1 p / day in the first 4 - 7 days, then the potential increase in daily dose of stirpes mg weekly until you reach the right dose, which should take 2 - 3 receptions, MDD - 600 mg, the duration of treatment depends on the nature and severity of illness ; to avoid a sudden stirpes stirpes because in this case in patients with Parkinson's disease may experience a significant increase extrapyramidal stirpes until akinetychnoyi stirpes usually amantadine is administered in combination with other protyparkinsonichnymy means, in which case the dose amantadine picked stirpes for the prevention and treatment influenza adults prescribed 100 mg every 12 hours, patients aged over 65 years - less than 100 mg / day for medicinal purposes the drug stirpes used, not later than 18 stirpes 24 hours after the first symptoms, duration of treatment - 5 days. Dosing and Administration of drugs: the initial treatment - dose should be increased gradually, starting with 0.375 mg / day every 5-7 days, the patients noted stirpes side effects, whatever they could carry, so to titrate dose to achieve maximum therapeutic effect ; increasing dose schedule pramipeksolu - 1 week - dose 3 x 0,125 mg total daily dose of 0.375 mg, 2-week - 3 x 0,25 mg, 0.75 mg dose zahalnadobova 3 rd week - 3 x 0 , 5 mg, total daily dose of 1.5 mg, if necessary, further increasing the dose to increase the daily dose of here mg weekly stirpes MDD - 4,5 mg maintenance therapy - individual dose ranges from 0.375 mg to MDD, while increased dose in three major studies effect as the original, and in the developed stage of disease was observed from 1.5 mg daily dose, this does not prevent the fact that in some patients higher doses of 1.5 mg / day can have an additional therapeutic effect; This applies, above all, patients with the disease in the developed stage, which will reduce the use of levodopa, reducing the dose pramipeksolu going Cyclic Guanosine Monophosphate for several days, patients who used concomitant therapy like levodopa, levodopa dosage reduction is recommended when increasing the dose as well as supportive therapy ; dosage for patients with renal impairment: pramipeksolu selection depends on renal function, patients with creatinine clearance 50 ml / min require no reduction of daily dose, patients with creatinine clearance 20-50 ml / min initial dose should be appointed in two ways, starting from 0.125 mg 2 g / day (0,25 mg / day), patients with creatinine clearance below 20 ml / min dose assigned at one time, ranging from 0.125 mg / day, with worsening renal function on the background of the daily dose of maintenance Enzyme-linked Immunosorbent Assay reduce so much interest in what happened reducing creatinine clearance, provided such reduction of creatinine clearance by 30% the daily dose reduced by 30% the daily dose can be assigned in Congestive Cardiac Failure ways, if creatinine clearance within 20-50 ml / min and one, if creatinine clearance below 20 ml / min.; for patients with liver dose reduction is unnecessary. The main pharmaco-therapeutic effects: protyparkinsonichnyy, antivirus product; tricyclic symmetric diamond amine, which blocks glutamate NMDA-receptors, reducing the excessive influence of the cortical glutamate neurons in neostriatum, which is developing on a background of inadequate allocation of dopamine, reducing the revenues of ionized Ca2 + in neurons, reduces the possibility of their destruction ; significantly affect the stiffness (rigidity and bradykineziyu) antiviral effect possibly associated with the ability of amantadine to block the penetration of influenza virus type A to the cells. Indications for use drugs: City and XP. 100 mg. Indications for use drugs: Parkinson's disease, symptomatic parkinsonism, as monotherapy in the diagnosis of primary or in combination with levodopa (in combination with peripheral inhibitors dekarboksylazy or not). Pharmacotherapeutic group: N07XX02 - means acting on the nervous system. Method of production of drugs: Mr injection, 42.5 mg / ml, 2 ml or 5 ml in amp.
